The expression of prostate-specific membrane antigen (PSMA) is elevated in prostate cancer cells, and its form circulating in blood is exploited for diagnostic purposes including monitoring of patients (Jeong and Kwak 2021). This evidence concerns the gene FOLH1 and prostate carcinoma.